/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
/PRNewswire/ -- Ademi LLP is investigating EQRx (Nasdaq: EQRX) for possible breaches of fiduciary duty and other violations of law in its transaction with...
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Shareholder rights law firm Robbins LLP is investigating EQRx, Inc. (NASDAQ: EQRX) to determine whether certain EQRx officers and directors violated securities laws and breached fiduciary duties to shareholders....
Indaptus (INDP) announces positive pre-clinical efficacy data from a poster presentation made at a scientific conference from its proprietary Decoy platform pre-clinical study. Stock is up 22%.
Novo Nordisk (NVO) increases annual guidance for the year 2023 on higher sales expectations for Ozempic and Wegovy.
Pharma Goliath Novo Nordisk (NVO) inks collaboration agreement with Aspect Biosystems to develop and commercialize transformative cell therapy treatments for type I diabetes patients.
Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.
Aurinia Pharmaceuticals (AUPH) announces the issue of its new and refined method-of-use patent, supplementing its existing patent, for Lupkynis to treat lupus nephritis. Shares are up 11%.
Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success.